Levetiracetam in der Behandlung des Status epilepticus – ein update

Zusammenfassung

Seit 2004 liegen Publikationen zum Einsatz von Levetiracetam beim Status epilepticus vor. In der vorliegenden Arbeit werden basierend auf einer PubMed-Literatur-Recherche vom 06.07.2018 die nach dem 12.12.2011 erschienenen Arbeiten zusammenfassend dargestellt und in der Diskussion mit den älteren Arbeiten verglichen. Es wurden 28 Behandlungsepisoden in Berichten über 1-2 Fälle und 412 Behandlungsepisoden in Fallserien und prospektiven Studien beschrieben. Dabei ließ sich aus den Fallserien und Studien ein hochwahrscheinlicher Mittelwert der Erfolgsrate für die Status-Durchbrechung von 55,0 %-59,4 % ableiten. Auf-grund des zu vermutenden verzögerten Wirkungseitritts des Levetiracetams ist sein Einsatz beim Status generalisierter tonisch-klonischer Anfälle dennoch zu hinterfragen. Als Loading-Dosis erscheinen 30 mg / kg KG angemessen

Abstract

Since 2004 several reports on the treatment of status epilepticus with levetiracetam have been published. In this review, the results of a PubMed-based search of publications December 12, 2011 - July 6, 2018 are summarized and compared to those of earlier publications. In total, 28 treatment episodes in case reports, each on one or two cases of treatment episodes, and 412 treatment episodes in case series and prospective studies were analyzed. Case series and prospective studies reported an average success rate for termination of status probably of 55,0 %-59,4 %. Since preclinical data suggest a delayed effect of levetiracetam, its use in the treatment of generalized convulsive status epilepticus appears still questionable. A loading dose of 30 mg / kg seems to be reasonable.

Schlüsselwörter

Levetiracetam - Erfolgsrate - Status epilepticus

Key words

Levetiracetam - status epilepticus - success rate

• Literatur

• 1 Fröscher W, Rösche J. Levetiracetam. Arzneimitteltherapie 2001; 19: 275-281 .
• 2 Arrigo A, Raiteri U, Ardizzone G. Levetiracetam monotherapy for the treatment of partial status epilepticus in a patient following a liver transplant. Epilpesia 2004; 45 (Suppl. 3): 145
• 3 Rösche J, Pohley I, Rantsch K. et al. Erfahrungen mit Levetiracetam in der Behandlung des Status epilepticus. Fortschr Neurol Psychiatr 2013; 81: 21-27 .
• 4 Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents. CNS Drugs 2017; 31: 327-334 .
• 5 Redecker J, Wittstock M, Benecke R. et al. Comparison of the effectiveness of four antiepileptic drugs in the treatment of status epilepticus according to four different efficacy criteria. Epilepsy Behav 2015; 49: 351-353 .
• 6 Redecker J, Wittstock M, Rösche J. The efficacy of different kinds of intravenously applied antiepileptic drugs in treatment of status epilepticus. How can it be determined? Epilepsy Behav 2017; 71: 35-38 .
• 7 Misra UK, Kalita J. A comparison of four antiepileptic drugs in status epilepticus: experience from India. Int J Neurosci 2016; 126: 1013-1019 .
• 8 Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol 2012; 259: 645-648 .
• 9 Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67: 340-342 .
• 10 Nakamura K, Inokuchi R, Daidoji H. et al. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. Medicine 2017; 96: 25(e7206)
• 11 McTague A, Keen R, Kumar R. et al. Appleton R. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children’s hospital. Seizure 2012; 21: 529-34 .
• 12 Tanriverdi S, Terek D, Koroglu OA. et al. Neonatal status epilepticus controlled with levetiracetam at Sturge Weber syndrome. Brain Dev. 2013; 35: 367-371
• 13 Chakravarthi S, Goyal MK, Modi M. et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci 2015; 22: 959-963 .
• 14 Mundlamuri RC, Sinha S, Subbakrishna DK. et al. Management of generalised convulsive status epilepticus (SE): A prospective randomized controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate, or levetiracetam – Pilot study. Epilepsy Res 2015; 114: 52-58 .
• 15 Lee YJ, Yum MS, Kim EH. et al. Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures. Korean J Pediatr 2016; 59: 35-39
• 16 Abend NS, Sanchez SM, Berg RA. et al. Treatment of electrographic seizures and status epilepticus in critically ill children: a single center experience. Seizure 2013; 22: 467-471 .
• 17 Khongkhatithum C, Thampratankul L, Wiwattanadittakul N. et al. Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures. Eur J Paediatr Neurol 2015; 19: 429-434 .
• 18 Grioni D, Furlan F, Canonico F. et al. Epilepsia partialis continua and generalized nonconvulsive status epilepticus during the course of argininemia: a report on two cases. Neuropediatrics 2014; 45: 123-128 .
• 19 Yamamuro K, Yoshino H, Tamura K. et al. Levetiracetam improves disinhibitory behavior in nonconvulsive status epilepticus. Ann Gen Psychiatry 2014; 13: 32
• 20 Lang N, Esser W, Evers S. et al. Intravenous levetiracetam in clinical practice – Results from an independent registry. Seizure 2015; 29: 109-113 .
• 21 Navarro V, Dagron C, Elie C. et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomized, double-blind phase 3 trial. Lancet Neurol 2016; 15: 47-55 .
• 22 Isgüder R, Güzel O, Ceylan G. et al. A comparison of intravenous levetiracetam and valproate for the treatment of refractory status epilepticus in Children. J Child Neurol 2016; 31: 1120-1126 .
• 23 Bachhuber A, Lasrich M, Halmer R. et al. Comparison of antiepileptic approaches in treatment of benzodizapine nonresponsive status epilepticus. CNS Neurosci Ther 2016; 22: 178-183 .
• 24 Fernández-Torrón R, Esteve-Belloch P, Palma JA. et al. Prolonged hemiplegia as the only symptom of a simple focal nonconvulsive status epilepticus. Rev Neurol 2012; 55: 253-254
• 25 Mader EC, Villemarette-Pittman NR, Kashirny SV. et al. Typical spike-and-wave activity in hypoxic-ischemic brain Injury and its implications for classifying nonconvulsive status epilepticus. Clin Med Insights Case Rep 2012; 5: 99-106
• 26 Khaburzania M, Beridze M. Non-convulsive statusepilepticus in comatose patients (case reports). Georgian Med News 2012; 207: 18-21 .
• 27 Isoda K, Tomoyasu C, Fujii N. et al. Levetiracetam induced aggravation to non-convulsive status epilepticus in a boy with Lennox-Gastaut syndrome. No To Hattatsu 2012; 44: 401-402 .
• 28 Badshah MB, Riaz H, Aslam S. et al. Complex partial non-convulsive status epilepticus masquerading as hepatic encephalopathy: a case report. J Med Case Rep 2012; 6: 422
• 29 Shein SL, Reynolds TQ, Gedela S. et al. Therapeutic hypothermia for refractory status epilepticus in a child with malignant migrating partial seizures of infancy and SCN1A mutation: a case report. Ther Hypothermia Temp Manag 2012; 2: 144-149 .
• 30 Moseley BD, DeGiorgio CM. Refractory status epilepticus treated with trigeminal nerve stimulation. Epilepsy Res 2014; 108: 600-603 .
• 31 Fernández-Torre JL, Burgueno P, Ballesteros MA. et al. Super-refractory nonconvulsive status epilepticus secondary to fat embolism: A clinical, electrophysiological, and pathological study. Epilepsy Behav 2015; 49: 184-188 .
• 32 Laswell EM, Chambers KD, Whitsel DR. et al. New-onset refractory status epilepticus in an adult with an atypical presentation of cat-scratch disease: successful treatment with high-dose corticosteroids. Pharmakotherapy 2015; 35: e106-110 .
• 33 Illán-Gala I, Díaz de Terán FJ, Alonso P. et al. Nonconvulsive status epilepticus secondary to paclitaxel administration. Epilepsy Behav Case Rep 2015; 5: 20-22 .
• 34 Ylikotila P, Ketola RA, Timonen S. et al. Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. Reprod Toxicol 2015; 57: 204-206 .
• 35 Tolunay O, Celik T, Kömür M. et al. A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature. Eur J Paediatr Neurol 2015; 19: 730-732 .
• 36 Egawa S, Hifumi T, Kawakita K. et al. Successful treatment of non-convulsive status epilepticus diagnosed using bedside monitoring by a combination of amplitude-integrated and two-channel simplified electroencephalography. Acute Med Surg 2015; 27: 167-170 .
• 37 Dömötör J, Clemens B. Focal motor seizures and status epilepticus provoked by mirtazapine. Ideggyogy Sz 2015; 68: 286-288 .
• 38 Paschen I, Walter U, Kamm C, Rösche J. Case report: absence-status as late reexacerbation of genetic epilepsy of adolescence. Acta Neurol Belg. 2016; 116: 675-676 .
• 39 Kim J, Shin JW. Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. Epileptic Disord 2017; 19: 104-108 .
• 40 Mysore CS, Murr N, Zabad R. et al. nonconvulsive status epilepticus resembling clinical absence with atypical EEG pattern. Case Rep Neurol Med 2017 ; doi 10.1155 / 2017 / 6 987 821
• 41 Bernardo S, Marchionni E, Prudente S. et al. Unusual association of SCN2A epileptic encephalopathy with severe cortical dysplasia detected by prenatal MRI. Eur J Paediatr Neurol 2017; 21: 587-590 .
• 42 Kurauchi Y, Yasaka M, Tokunaga K. et al. Non-Convulsive status epilepticus caused by hyponatremia in an elderly woman: A case report. Brain Nerve 2017; 69: 489-492 .
• 43 Ibrahim TF, Sweis RT, Nockels RP. Reversible postoperative blindness caused by bilateral status epilepticus amauroticus following thoracolumbar deformity correction: case report. J Neurosurg Spine 2017; 27: 63-67 .
• 44 Al Busaidi M, Burad J, Al-Belushi A. et al. Super refractory status epilepticus in Hashimoto’s encephalopathy. Oman Med J 2017; 32: 247-250 .
• 45 Fernández-Torre JL, Paramio-Paz A, Rodriguez-Borregán JC. et al. Super-refractory nonconvulsive status epilepticus due to self-poisoning with metaldehyde. J Clin Neurosci 2018; 47: 134-136 .
• 46 Kim JS, Lee JH, Ryu HW. et al. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. Pediatr Emerg Care 2014; 30: 525-528 .
• 47 Atmaca MM, Orhan EK, Bebek N. et al. Intravenous levetiracetam treatment in status epilepticus: A prospective study. Epilepsy Res 2015; 114: 13-22 .
• 48 Gujjar AR, Nandhagopal R, Jacob PC. et al. Intravenous Levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure 2017; 49: 8-12 .
• 49 Atmaca MM, Bebek N, Baykan B. et al. Predictors of outcome and refractoriness in status epilepticus: A prospective study. Epilepsy Behav 2017; 75: 158-164 .
• 50 Doheny HC, Ratnaraj N, Whittington MA. et al. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999; 34: 161-168 .
• 51 Nicolas J-M, Hannestad J, Holden D. et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016; 57: 201-209 .
• 52 Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012; 21: 233-236 .
• 53 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus – Report of the ILAE task force on classification of status epilepticus. Epilepsia 2015; 56: 1515-1523
• 54 Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006; 8: 651-654
• 55 Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009; 14: 215-218